Kura Oncology Q1 net loss $49.5M, cash $527M; ziftomenib gets BTD for NPM1-mutant AML

Kura Oncology, Inc.

2024-Q1 EPS reported -$0.59

Net loss of $49.5M in Q1 2024 vs $34.1M in Q1 2023; cash $527M provides runway into 2027.
FDA granted Breakthrough Therapy Designation to ziftomenib for relapsed/refractory NPM1-mutant AML based on KOMET-001 data.
Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment of 85 patients by mid-2024.
Positive preliminary combo data: 100% CR rate in newly diagnosed with ziftomenib + 7+3; 53% ORR in R/R with venetoclax/azacitidine.
First patient dosed with KO-2806 + cabozantinib in RCC; on track to dose with adagrasib in KRASG12C NSCLC by mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kura Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $49.5 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $49.5 million
Result: reported results

Exact text from the filing

Kura Oncology, Inc. (the "Company") issued a press release announcing the Company's financial results for the first quarter ended March 31, 2024 and providing a corporate update.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.